Individuals with skin concerns, such as hyperpigmentation or dullness
What the clinical data has reported: Phase 2 trials of Retatrutide (Jastreboff et al., NEJM 2023, and follow-ups) reported: - Dose-dependent body weight reduction across 24- and 48-week dosing intervals - Reductions in liver fat content measured by MRI-proton density fat fraction (MRI-PDFF) in populations with metabolic dysfunction-associated steatotic liver disease (MASLD) - Glycaemic marker improvement (HbA1c, fasting glucose) in type 2 diabetes cohorts - Dose-related gastrointestinal adverse effects consistent with the GLP-1/GIP class nausea, vomiting, diarrhoea Important: these are clinical trial findings in regulated patient populations
Refrigeration is recommended for maximum effectiveness
Yes, it supports fat metabolism by helping the body convert stored fat into energy during workouts
44,45 In response to overnutrition, obesity and insulin resistance, beta-cells adapt by increasing their mass and/or number, both of which result in increased capacity of insulin secretion
